Retension Pharmaceuticals, Inc. — Form SCHEDULE 13D
Filed October 14, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 22/100
What the filing says
Keller Eric L. filed a Schedule 13D with the SEC on 2026-10-14 regarding beneficial ownership in Retension Pharmaceuticals, Inc. (a pharmaceutical preparations company, Delaware incorporated). The filing address lists Redux Therapeutics LLC and Retension Pharmaceuticals at separate Virginia locations. No specific ownership percentage, share count, acquisition date, or dollar amount is disclosed in the header information provided.
Why this rating
Schedule 13D is routine mandatory disclosure; no material facts (shares acquired, %, price, date) are visible in the header stub. Cannot assess impact without complete filing content.
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.